alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,026–1,050 of 1,076 studies (page 42 of 44) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 1,076 studies tagged parkinson — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuromolecular medicine 2003-01-01

Abnormal interactions and misfolding of synaptic proteins in the nervous system are being extensively explored as important pathogenic events resulting in neurodegeneration in various neurological disorders. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

New therapeutic strategy for Parkinson's and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medicinal chemistry 2010-01-01

The development of potential neuroprotective therapies for neurodegenerative diseases (Parkinson's and Alzheimer's Disease) must be based on understanding their molecular and biochemical pathogenesis. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Movement disorders : official journal of the Movement Disorder Society 2009-01-01

Although Parkinson's disease with later dementia (PDD) and dementia with Lewy bodies (DLB) are pathologically characterized by the presence of intraneuronal Lewy inclusion bodies, amyloid deposition is also associated to varying degrees with both these disorders. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Neuroepidemiology 1994-01-01

In 1986 in the Kuthar Valley in the Anantnag District of south Kashmir (northwestern India), we studied the population to ascertain the prevalence and pattern of various neurological diseases. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A study of emotional processing in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Brain and cognition 1998-10-01

This study investigated three aspects of processing materials with emotional content in patients with idiopathic Parkinson's disease (PD): the ability to produce affective prosody, to discriminate affectively loaded speech, and to detect the surprise element in humorous sketches. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cognitive impairment in motor neuron disease with bulbar onset

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2001-03-01

This study adds further arguments for a cognitive impairment in MND/ALS. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Hippocampal mitophagy alterations in MAPT-associated frontotemporal dementia with parkinsonism

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Acta Neuropathologica Communications 2025-02-24

The enzyme pair PINK1 and PRKN together orchestrates a cytoprotective mitophagy pathway that selectively tags damaged mitochondria with phospho-serine 65 ubiquitin (pS65-Ub) and directs them for autophagic-lysosomal degradation (mitophagy). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[P2–526]: GEOGRAPHICAL VARIATIONS IN DIAGNOSTIC RATES FOR DEMENTIA WITH LEWY BODIES IN CLINICAL SERVICES

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Alzheimer s & Dementia 2017-07-01

Clinical and population-based epidemiological studies report variation in the observed prevalence and incidence of dementia with Lewy bodies (DLB). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Preclinical and Prodromal Frontotemporal Dementia: Challenges and Opportunities

✓ Peer-reviewed alzhub usefulness score 34 out of 100. International Journal of Translational Medicine 2025-11-15

Frontotemporal lobar degeneration (FTLD) represents a heterogeneous group of neurodegenerative disorders with overlapping clinical, pathological, and genetic characteristics. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dysfunctional default mode and visual networks underlie cognitive deficits in dementia with Lewy bodies: a resting-state fMRI study

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Frontiers in Aging Neuroscience 2025-11-19

DLB is characterized by DMN and visual network dysfunction, disrupted local neural activity, and impaired global network integration. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Vulnerability of anterior cingulate Von Economo neurons to FTLD-tauopathies in behavioral variant frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Cerebral Cortex 2026-02-01

Von Economo neurons (VENs) are unique spindle-shaped neurons that primarily reside in the anterior cingulate (ACC) and fronto-insular (FI) cortices. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Behavioral Variant Frontotemporal Dementia With C9orf72 Intermediate Repeat Expansion

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer Disease & Associated Disorders 2026-01-01

Hexanucleotide repeat expansion in the chromosome 9 open reading frame 72 ( C9orf72 ) gene has been identified as the most common genetic cause of both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Rapidly Progressive Dementia After Platelet-Rich Plasma Therapy: A Case of Sporadic Creutzfeldt-Jakob Disease in the Context of Chronic Ehrlichiosis

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Cureus 2025-08-27

Prion diseases are fatal neurological disorders characterized by the accumulation of abnormal proteins in the central nervous system, leading to rapid neurodegeneration. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Unraveling the Link Between Bullous Pemphigoid and Neurological Disease: A Single-center Study of 257 Patients

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Actas dermo-sifiliograficas 2025-04-07

Our case series highlighted the relevance of neurological comorbidities in BP patients; although the pathogenesis is still to be elucidated, the neuroinflammation present in neurodegenerative diseases could explain the neurocutaneous link and the chronological relationship between these entities. 3 key findings →

Participants: 257 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 1,075 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events